Valiant Laboratories Limited Stock Price Today (NSE: VALIANTLAB)
Fundamental Score
Valiant Laboratories Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Valiant Laboratories Limited share price today is ₹128.40, up +0.05% on NSE/BSE as of 30 October 2026. Valiant Laboratories Limited (VALIANTLAB) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹697.37 (Cr). The 52-week high for VALIANTLAB share price is ₹141.38 and the 52-week low is ₹49.51. At a P/E ratio of 43.53x, VALIANTLAB is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of -1.20% and a debt-to-equity ratio of 0.14.
Valiant Laboratories Limited Share Price Chart — NSE/BSE Historical Performance
Valiant Laboratories Limited share price chart: 15.17% return over the past month. 52-week high ₹141.38, 52-week low ₹49.51.
Valiant Laboratories Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹130.88 | ₹130.88 | ₹128.33 | ₹128.40 | 11.69K (Cr) | |
| ₹125.00 | ₹128.33 | ₹125.00 | ₹128.33 | 37.93K (Cr) | |
| ₹120.91 | ₹125.82 | ₹120.90 | ₹125.82 | 86.80K (Cr) | |
| ₹123.36 | ₹123.36 | ₹123.36 | ₹123.36 | 6.31K (Cr) | |
| ₹125.87 | ₹125.87 | ₹125.87 | ₹125.87 | 58.28K (Cr) | |
| ₹128.43 | ₹128.43 | ₹128.43 | ₹128.43 | 9.96K (Cr) | |
| ₹131.05 | ₹131.05 | ₹131.05 | ₹131.05 | 11.51K (Cr) | |
| ₹138.40 | ₹138.40 | ₹133.72 | ₹133.72 | 1.06L (Cr) | |
| ₹141.38 | ₹141.38 | ₹132.00 | ₹140.75 | 1.96L (Cr) | |
| ₹125.25 | ₹134.65 | ₹125.25 | ₹134.65 | 1.05L (Cr) |
Valiant Laboratories Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹128.70 | ₹141.38 | ₹113.00 | ₹128.40 | -0.23% | |
| ₹96.34 | ₹132.25 | ₹91.53 | ₹126.23 | +31.03% | |
| ₹86.53 | ₹110.70 | ₹86.31 | ₹96.34 | +11.34% | |
| ₹66.99 | ₹66.99 | ₹59.15 | ₹61.74 | -7.84% | |
| ₹77.44 | ₹81.49 | ₹64.60 | ₹65.00 | -16.06% | |
| ₹79.38 | ₹82.20 | ₹73.00 | ₹77.44 | -2.44% | |
| ₹54.00 | ₹83.70 | ₹53.99 | ₹77.82 | +44.11% | |
| ₹53.10 | ₹63.70 | ₹49.51 | ₹51.62 | -2.79% | |
| ₹57.00 | ₹68.50 | ₹56.00 | ₹57.28 | +0.49% | |
| ₹70.35 | ₹75.40 | ₹56.53 | ₹58.75 | -16.49% | |
| ₹66.29 | ₹79.90 | ₹63.86 | ₹70.00 | +5.60% | |
| ₹82.00 | ₹85.20 | ₹65.30 | ₹66.34 | -19.10% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Valiant Laboratories Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Valiant Laboratories Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of VALIANTLAB across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Robust Profit Growth (1058.93%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (146.22%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.14)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Healthy Liquidity Position (Current Ratio: 1.91)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Balanced Promoter Holding (74.94%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Below-Average Return on Equity (-1.20%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (0.78%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 43.53x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Weak Interest Coverage (1.40x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-187.41 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.04%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Valiant Laboratories Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Valiant Laboratories Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Valiant Laboratories LimitedValiant Laborat...Selected✓ VALIANTLAB • 543998 | 39.3/100 | ₹128.40₹128 | ₹697.37₹697.37 | 43.53Average 43.5 Average | -1.20%Poor -1.20% Poor | 0.78%Poor 0.78% Poor | 0.14Excellent 0.1 Excellent | — — | — — | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 72.9/100 | ₹1758.80₹1759 | ₹421988.88₹421988.88 | 34.90Average 34.9 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 67.2/100 | ₹9144.50₹9145 | ₹242329.25₹242329.25 | 82.97Average 83.0 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 54.8/100 | ₹4558.90₹4559 | ₹154300.53₹154300.53 | 72.83Average 72.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 71.6/100 | ₹1123.00₹1123 | ₹112075.40₹112075.40 | 25.03Average 25.0 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 53.5/100 | ₹2060.10₹2060 | ₹111296.90₹111296.90 | 101.68Average 101.7 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 35.2/100 | ₹1325.10₹1325 | ₹107048.20₹107048.20 | 31.75Average 31.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 36.5/100 | ₹1233.00₹1233 | ₹102955.50₹102955.50 | 31.87Average 31.9 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1666.90₹1667 | ₹95913.43₹95913.43 | 26.05Average 26.0 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 59.7/100 | ₹2275.50₹2276 | ₹93978.15₹93978.15 | 45.98Average 46.0 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 77.1/100 | ₹1961.60₹1962 | ₹89694.16₹89694.16 | 16.21Average 16.2 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price421988.88 Cr
- Divi's Laboratories Limited share price242329.25 Cr
- Torrent Pharmaceuticals Limited share price154300.53 Cr
- Zydus Lifesciences Limited share price112075.40 Cr
- Laurus Labs Limited share price111296.90 Cr
Valiant Laboratories Limited PE Ratio History
Historical price-to-earnings ratio for VALIANTLAB — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹0.12 | ₹111.13 | 921x |
| FY 2023 | ₹6.19 | ₹173.20 | 28x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Valiant Laboratories Limited Quarterly Performance
Latest quarterly metrics for VALIANTLAB — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
146.22%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
1058.93%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Valiant Laboratories Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for VALIANTLAB — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Valiant Laboratories Limited Financial Statements
Annual income statement, balance sheet and cash flow for Valiant Laboratories Limited (VALIANTLAB) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Valiant Laboratories Limited
About VALIANTLAB (Valiant Laboratories Limited)
Valiant Laboratories Ltd is a dynamic pharmaceutical company carving a niche in the production and distribution of high-quality active pharmaceutical ingredients (APIs) and special...ty chemicals. Strategically headquartered in India, Valiant Laboratories serves both domestic and international markets with a commitment to excellence and stringent quality control. The company’s strength lies in its ability to manufacture essential pharmaceutical components, building a reliable supply chain for its partners across the globe. With a focus on continuous improvement and innovative manufacturing processes, Valiant Laboratories stands as a trusted source for pharmaceutical solutions, contributing to the advancement of healthcare through its dedication to producing dependable and effective ingredients. At the heart of Valiant Laboratories' product portfolio is the versatile paracetamol, manufactured in compliance with a comprehensive range of pharmacopoeial standards including Indian, British, European, and United States specifications. This ensures the company meets diverse regulatory requirements and customer needs worldwide. Beyond paracetamol, Valiant Laboratories expands its offerings with a selection of specialty chemicals designed to cater to specific market demands. This dual focus allows the company to operate within a broad scope of the pharmaceutical industry, catering to both established needs and emerging opportunities. Through its commitment to stringent quality standards and comprehensive product range, Valiant Laboratories is recognized as a provider of reliable pharmaceutical ingredients. Originally established as Bharat Chemicals, Valiant Laboratories evolved to embody a renewed commitment to innovation and global reach. The strategic name change signifies a transformational phase, reflecting the company's ambitious vision and dedication to expanding its presence in the international pharmaceutical landscape. Today, Valiant Laboratories operates with a forward-thinking approach, emphasizing research and development to stay ahead of market trends and deliver cutting-edge solutions. By continuously investing in infrastructure and technology, Valiant Laboratories aims to reinforce its position as a key player in the API manufacturing sector, ultimately contributing to the improved health and wellbeing of individuals worldwide.
Company Details
Key Leadership
VALIANTLAB Share Price: Frequently Asked Questions
What is the current share price of Valiant Laboratories Limited?
Valiant Laboratories Limited (VALIANTLAB) trades at ₹128.40 on NSE and BSE. Market cap ₹697.37 (Cr). Educational data only.
What is the P/E ratio of Valiant Laboratories Limited?
Valiant Laboratories Limited has a P/E of 43.53x vs industry average 34.89x.
What is the Bull Run score for Valiant Laboratories Limited?
Valiant Laboratories Limited has a Bull Run score of 39.3/100 based on 25+ financial parameters.
Does Valiant Laboratories Limited pay dividends?
Valiant Laboratories Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Valiant Laboratories Limited?
Valiant Laboratories Limited has ROE of -1.20%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Valiant Laboratories Limited?
Valiant Laboratories Limited has debt-to-equity of 0.14.
Is Valiant Laboratories Limited a good investment?
Bull Run gives Valiant Laboratories Limited a score of 39.3/100. This is not investment advice — consult a SEBI-registered advisor.